In summary, molecular targeting of GAPDH via percutaneous injection of either an inhibitor, 3-BrPA, or shRNA blocks tumor progression demonstrating the therapeutic potential of targeting GAPDH in HCC. The gene discussed is GAPDH; the disease is hepatocellular carcinoma.